🇺🇸 Repamipide in United States

11 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Platelet Count Decreased — 2 reports (18.18%)
  2. Alanine Aminotransferase Increased — 1 report (9.09%)
  3. Anorexia — 1 report (9.09%)
  4. Aspartate Aminotransferase Increased — 1 report (9.09%)
  5. Blood Pressure Decreased — 1 report (9.09%)
  6. Blood Thyroid Stimulating Hormone Increased — 1 report (9.09%)
  7. Cardiac Failure — 1 report (9.09%)
  8. Chest Discomfort — 1 report (9.09%)
  9. Cholestasis — 1 report (9.09%)
  10. Cytomegalovirus Infection — 1 report (9.09%)

Source database →

Other Other approved in United States

Frequently asked questions

Is Repamipide approved in United States?

Repamipide does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Repamipide in United States?

King Chulalongkorn Memorial Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.